GlassScriptPhysician profile
Juan Mujica
NPI 1760488282
$909.19
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $78.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $102.60 | 2019 | |
| Janssen Biotech, INC. | $84.49 | 2019-2020 | |
| Pfizer INC. | $80.56 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $76.08 | 2019 | |
| Sun Pharmaceutical Industries INC. | $73.24 | 2019-2020 | |
| Genzyme Corporation | $69.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $67.19 | 2019 | |
| Celgene Corporation | $41.58 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $35.20 | 2019 | |
| Galderma Laboratories, L.P. | $33.65 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $28.89 | 2019 | |
| Almirall LLC | $22.83 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.92 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.24 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Mujica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.